Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Neutral 52.2%

Neg 0% Neu 52.2% Pos 0%

Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:CNMD) with a Neutral and raises the price target from $39 to $45.